Myelofibrosis future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
Future and investigational therapies involve immunomodulatory drugs, histone deacetylase inhibitors, newer generation drugs of already existing medications and drugs targeting pathways other than the JAK/STAT. The goal is to limit the need for allogeneic stem cell transplantation.
Future or Investigational Therapies
- Future or investigational therapies involve:
- Immunomodulatory drugs[1]
- Histone deacetylase inhibitors
- Second-generation Janus kinase 1/2 inhibitors
References
- ↑ Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M (November 2018). “Novel treatments to tackle myelofibrosis”. Expert Rev Hematol. 11 (11): 889–902. doi:10.1080/17474086.2018.1536538. PMID 30324817.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH